Story

Zoetis Stock Slides After Slashing Full-Year Earnings Guidance

ENTHMSVIIDZHZH-TWJAKOHI
Aug 6, 20261 min read
Zoetis Stock Slides After Slashing Full-Year Earnings Guidance
Text size
Background

Shares of Zoetis (ZTS) fell sharply in pre-market trading after the animal health giant significantly cut its full-year earnings forecast, alarming investors and overshadowing its second-quarter results.

Disappointing Outlook Drives Sell-Off

While Zoetis reported second-quarter earnings per share (EPS) of $1.87, narrowly beating the consensus estimate of $1.86, its revenue failed to meet expectations. The company posted quarterly revenue of $2.5 billion, flat year-over-year and just shy of the $2.51 billion analysts had forecast.

The key driver for the stock's decline was the company's revised full-year 2026 guidance. Management now expects EPS in the range of $6.15 to $6.25, a figure substantially below the analyst consensus of $6.87. This sharp reduction signals that the company anticipates no near-term recovery in its core business operations.

Persistent Headwinds in Core U.S. Market

The bleak forecast reflects a prolonged period of difficulty for Zoetis's crucial U.S. companion animal segment. The division has been grappling with multiple challenges, according to market reports, including:

Sample IUX Markets – In-articleAd
  • Mounting competition from rivals.
  • Increased price sensitivity among consumers.
  • Safety-related concerns surrounding its key osteoarthritis monoclonal antibody products, Librela and Solensia.

These ongoing issues have led analysts to adopt a cautious stance, with many trimming price targets in the months leading up to the earnings release.

Leadership Transition and Stock Performance

Adding a layer of uncertainty, Zoetis also announced a leadership transition. Jay Saccaro will assume the newly created combined role of Executive Vice President, CFO, and COO, effective August 17, 2026.

The negative market reaction pushed the stock toward its 52-week low of $71.47. Shares have lost roughly half their value over the past year from a 52-week high of $160.48, with the latest guidance cut prompting investors to reassess the company's path to an operational recovery.

Read next

More on Stocks
Back to latest news

LATEST